Texas Specialty Pharmacy $48.5M
2025 Gross Estimate Revenue: $60M
2025 Gross Estimate EBITDA: $7.2M
The seller seeks strategic partners with extensive healthcare industry experience, established networks within the pharmaceutical sector, and sufficient capital resources to complete the transaction. Ideal candidates possess operational expertise to support continued growth and expansion initiatives.
The company's performance is on track for 2026 with estimated gross revenue $70M and EBITDA of $9M
The company has multiple locations and specializes in: Sterile/Non-Sterile Compounding and many more specialties.
The company's management team and staff can stay on for a smooth transition.
Contact us.
